These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1028957)

  • 1. Influence of dopaminergic agonists and antagonists on serum prolactin concentrations in the rat.
    Horowski R; Gräf HJ
    Neuroendocrinology; 1976; 22(3):273-86. PubMed ID: 1028957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of dopaminergic modulators in a tier I screening battery for identifying endocrine-active compounds (EACs).
    O'Connor JC; Davis LG; Frame SR; Cook JC
    Reprod Toxicol; 2000; 14(3):193-205. PubMed ID: 10838120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding site of salsolinol: its properties in different regions of the brain and the pituitary gland of the rat.
    Homicskó KG; Kertész I; Radnai B; Tóth BE; Tóth G; Fülöp F; Fekete MI; Nagy GM
    Neurochem Int; 2003 Jan; 42(1):19-26. PubMed ID: 12441164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats.
    Mueller GP; Simpkins J; Meites J; Moore KE
    Neuroendocrinology; 1976; 20(2):121-35. PubMed ID: 958594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine effects of neuropsychotropic drugs and their possible influence on toxic reactions in animals and man -- the role of the dopamine-prolactin system.
    Horowski R; Gräf KJ
    Arch Toxicol Suppl; 1979; (2):93-104. PubMed ID: 288372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological manipulation of anterior pituitary dopamine content in the male rat: relationship to serum prolactin concentration and lysosomal enzyme activity.
    Demarest KT; Riegle GD; Moore KE
    Endocrinology; 1984 Aug; 115(2):493-500. PubMed ID: 6745164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats.
    Gräf KJ; Neumann F; Horowski R
    Endocrinology; 1976 Mar; 98(3):598-605. PubMed ID: 1261489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenohypophysial dopamine content and prolactin secretion in the aged male and female rat.
    Demarest KT; Moore KE; Riegle GD
    Endocrinology; 1985 Apr; 116(4):1316-23. PubMed ID: 3971917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between endogenous dopamine and dopamine agonists at release modulatory receptors: multiple effects of neuronal uptake inhibitors on transmitter release.
    Hoffmann IS; Talmaciu RK; Cubeddu LX
    J Pharmacol Exp Ther; 1986 Aug; 238(2):437-46. PubMed ID: 2942676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. I. Release in the absence of vesicular transmitter stores.
    Parker EM; Cubeddu LX
    J Pharmacol Exp Ther; 1986 Apr; 237(1):179-92. PubMed ID: 3007736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or alpha-methyl-p-tyrosine pre-treated mice.
    Dolphin AC; Jenner P; Marsden CD
    Pharmacol Biochem Behav; 1976 Jun; 4(6):661-70. PubMed ID: 981283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice.
    Horowski R; Wachtel H
    Eur J Pharmacol; 1976 Apr; 36(2):373-83. PubMed ID: 945166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms involved in the prolactin-releasing effect of benserazide.
    Parati EA; Penalva A; Bondiolotti GP; Parenti M; Locatelli V; Picotti GB; Cocchi D; Müller EE
    Eur J Pharmacol; 1984 Jun; 101(3-4):215-21. PubMed ID: 6468496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibition of phosphatidylinositol turnover: a possible postreceptor mechanism for the prolactin secretion-inhibiting effect of dopamine.
    Canonico PL; Valdenegro CA; MacLeod RM
    Endocrinology; 1983 Jul; 113(1):7-14. PubMed ID: 6861715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dopamine agonists and antagonists on DOPA formation in the substantia nigra.
    Argiolas A; Melis MR; Fadda F; Serra G; Gessa GL
    J Neurochem; 1982 Jan; 38(1):75-9. PubMed ID: 6809898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of dopaminergic and noradrenergic mechanisms in Metrazole convulsions in mice.
    Dadkar VN; Dahanukar SA; Sheth UK
    Indian J Med Res; 1979 Sep; 70():492-4. PubMed ID: 535961
    [No Abstract]   [Full Text] [Related]  

  • 17. Locomotor hyperactivity induced by MK-801 in rats.
    Maj J; Rogóz Z; Skuza G
    Pol J Pharmacol Pharm; 1991; 43(6):449-58. PubMed ID: 1687944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of apomorphine, alpha-methylparatyrosine, haloperidol and reserpine on DOPA production in clonal cell lines (PC-12 and N1E-115).
    Bräutigam M; Laschinski G; Kittner B; Herken H
    Biochem Pharmacol; 1985 Apr; 34(7):941-7. PubMed ID: 3921032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent increase in plasma prolactin after pituitary stalk section: role of posterior pituitary dopamine.
    Murai I; Garris PA; Ben-Jonathan N
    Endocrinology; 1989 May; 124(5):2343-9. PubMed ID: 2495929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resumption of prolactin secretion after dopaminergic inhibition: differential effects of dopamine and its agonists.
    Woolf PD
    Am J Physiol; 1981 Jun; 240(6):E700-4. PubMed ID: 7246736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.